

IN THE CLAIMS

Claims 1-33 were canceled without prejudice or disclaimer of the subject matter thereof in the first preliminary amendment.

Claims 34 - 53 are canceled without prejudice or disclaimer of the subject matter thereof.

Please add new claims 54 - 66 as follows:

1-53 (Canceled)

54. (New) A method of treating cancer comprising contacting a cancer cell with an effective amount of a modulator of expression of SEQ ID NO:5, wherein modulation is selected from the group consisting of up-regulation and down-regulation of expression of SEQ ID NO:5.

55. (New) The method of Claims 54, wherein the cancer is selected from the group consisting of ABL1 protooncogene, AIDS Related Cancers, Acoustic Neuroma, Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia, Adenocystic carcinoma, Adrenocortical Cancer, Agnogenic myeloid metaplasia, Alopecia, Alveolar soft-part sarcoma, Anal cancer, Angiosarcoma, Aplastic Anaemia, Astrocytoma, Ataxia-telangiectasia, Basal Cell Carcinoma (Skin), Bladder Cancer, Bone Cancers, Bowel cancer, Brain Stem Glioma, Brain and CNS Tumors, Breast Cancer, CNS tumors, Carcinoid Tumors, Cervical Cancer, Childhood Brain Tumors, Childhood Cancer, Childhood Leukaemia, Childhood Soft Tissue Sarcoma, Chondrosarcoma, Choriocarcinoma, Chronic Lymphocytic Leukaemia, Chronic Myeloid Leukaemia, Colorectal Cancers, Cutaneous T-Cell Lymphoma, Dermatofibrosarcoma-protuberans, Desmoplastic-Small-Round-Cell-Tumor, Ductal Carcinoma, Endocrine Cancers, Endometrial Cancer, Ependymoma, Esophageal Cancer, Ewing's Sarcoma, Extra-Hepatic Bile Duct Cancer, Eye Cancer, Eye: Melanoma, Retinoblastoma, Fallopian Tube cancer, Fanconi Anaemia, Fibrosarcoma, Gall Bladder Cancer, Gastric Cancer, Gastrointestinal Cancers, Gastrointestinal-Carcinoid-Tumor, Genitourinary Cancers, Germ Cell Tumors, Gestational-Trophoblastic-Disease, Glioma, Gynaecological Cancers, Haematological Malignancies, Hairy Cell Leukaemia, Head and Neck Cancer, Hepatocellular Cancer, Hereditary Breast Cancer, Histiocytosis, Hodgkin's

Second Preliminary Amendment
U.S. Application No.10/567,983
Ref. No. 007193-20 US

2

Disease, Human Papillomavirus, Hydatidiform mole, Hypercalcemia, Hypopharynx Cancer, IntraOcular Melanoma, Islet cell cancer, Kaposi's sarcoma, Kidney Cancer, Langerhan's-Cell-Histiocytosis, Laryngeal Cancer, Leiomyosarcoma, Leukaemia, Li-Fraumeni Syndrome, Lip Cancer, Liposarcoma, Liver Cancer, Lung Cancer, Lymphedema, Lymphoma, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Male Breast Cancer, Malignant-Rhabdoid-Tumor-of-Kidney, Medulloblastoma, Melanoma, Merkel Cell Cancer, Mesothelioma, Metastatic Cancer, Mouth Cancer, Multiple Endocrine Neoplasia, Mycosis Fungoides, Myelodysplastic Syndromes, Myeloma, Myeloproliferative Disorders, Nasal Cancer, Nasopharyngeal Cancer, Nephroblastoma, Neuroblastoma, Neurofibromatosis, Nijmegen Breakage Syndrome, Non-Melanoma Skin Cancer, Non-Small-Cell-Lung-Cancer-(NSCLC), Ocular Cancers, Oesophageal Cancer, Oral cavity Cancer, Oropharynx Cancer, Osteosarcoma, Ovarian Cancer, Pancreas Cancer, Paranasal Cancer, Parathyroid Cancer, Parotid Gland Cancer, Penile Cancer, Peripheral-Neuroectodermal-Tumors, Pituitary Cancer, Polycythemia vera, Prostate Cancer, Rare-cancers-and-associated-disorders, Renal Cell Carcinoma, Retinoblastoma, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Salivary Gland Cancer, Sarcoma, Schwannoma, Sezary syndrome, Skin Cancer, Small Cell Lung Cancer (SCLC), Small Intestine Cancer, Soft Tissue Sarcoma, Spinal Cord Tumors, Squamous-Cell-Carcinoma-(skin), Stomach Cancer, Synovial sarcoma, Testicular Cancer, Thymus Cancer, Thyroid Cancer, Transitional-Cell-Cancer-(bladder), Transitional-Cell-Cancer-(renal-pelvis/-ureter), Trophoblastic Cancer, Urethral Cancer, Urinary System Cancer, Uroplakins, Uterine sarcoma, Uterus Cancer, Vaginal Cancer, Vulva Cancer, Waldenstrom's-Macroglobulinemia and Wilms' Tumor.

56. (New) The method according to Claim 55, wherein the cancer is selected from the group consisting of cancer of the breast, cancer of the kidney, cancer of the cervix, cancer of the lung, cancer of the rectum, cancer of the small intestine, cancer of the stomach, cancer of the ovary, cancer of the uterus, cancer of the vulva, cancer of the liver, cancer of the thyroid and cancer of the pancreas.

57. (New) A method of treating cancer comprising contacting a cancer cell with an effective amount of a modulator of the activity of a protein encoded by SEQ ID NO:5, wherein modulation is selected from the group consisting of increasing and decreasing protein activity.

58. (New) The method of Claim 57, wherein the cancer is selected from the group consisting of ABL1 protooncogene, AIDS Related Cancers, Acoustic Neuroma, Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia, Adenocystic carcinoma, Adrenocortical Cancer, Agnogenic myeloid metaplasia, Alopecia, Alveolar soft-part sarcoma, Anal cancer, Angiosarcoma, Aplastic Anaemia, Astrocytoma, Ataxia-telangiectasia, Basal Cell Carcinoma (Skin), Bladder Cancer, Bone Cancers, Bowel cancer, Brain Stem Glioma, Brain and CNS Tumors, Breast Cancer, CNS tumors, Carcinoid Tumors, Cervical Cancer, Childhood Brain Tumors, Childhood Cancer, Childhood Leukaemia, Childhood Soft Tissue Sarcoma, Chondrosarcoma, Choriocarcinoma, Chronic Lymphocytic Leukaemia, Chronic Myeloid Leukaemia, Colorectal Cancers, Cutaneous T-Cell Lymphoma, Dermatofibrosarcoma-protuberans, Desmoplastic-Small-Round-Cell-Tumor, Ductal Carcinoma, Endocrine Cancers, Endometrial Cancer, Ependymoma, Esophageal Cancer, Ewing's Sarcoma, Extra-Hepatic Bile Duct Cancer, Eye Cancer, Eye: Melanoma, Retinoblastoma, Fallopian Tube cancer, Fanconi Anaemia, Fibrosarcoma, Gall Bladder Cancer, Gastric Cancer, Gastrointestinal Cancers, Gastrointestinal-Carcinoid-Tumor, Genitourinary Cancers, Germ Cell Tumors, Gestational-Trophoblastic-Disease, Glioma, Gynaecological Cancers, Haematological Malignancies, Hairy Cell Leukaemia, Head and Neck Cancer, Hepatocellular Cancer, Hereditary Breast Cancer, Histiocytosis, Hodgkin's Disease, Human Papillomavirus, Hydatidiform mole, Hypercalcemia, Hypopharynx Cancer, IntraOcular Melanoma, Islet cell cancer, Kaposi's sarcoma, Kidney Cancer, Langerhan's-Cell-Histiocytosis, Laryngeal Cancer, Leiomyosarcoma, Leukaemia, Li-Fraumeni Syndrome, Lip Cancer, Liposarcoma, Liver Cancer, Lung Cancer, Lymphedema, Lymphoma, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Male Breast Cancer, Malignant-Rhabdoid-Tumor-of-Kidney, Medulloblastoma, Melanoma, Merkel Cell Cancer, Mesothelioma, Metastatic Cancer, Mouth Cancer, Multiple Endocrine Neoplasia, Mycosis Fungoides, Myelodysplastic Syndromes, Myeloma, Myeloproliferative Disorders, Nasal Cancer, Nasopharyngeal Cancer, Nephroblastoma, Neuroblastoma, Neurofibromatosis, Nijmegen Breakage Syndrome, Non-Melanoma Skin Cancer, Non-Small-Cell-Lung-Cancer-(NSCLC), Ocular Cancers, Oesophageal Cancer, Oral cavity Cancer, Oropharynx Cancer, Osteosarcoma, Ovarian Cancer, Pancreas Cancer, Paranasal Cancer, Parathyroid Cancer, Parotid Gland Cancer, Penile Cancer, Peripheral-Neuroectodermal-Tumors, Pituitary Cancer, Polycythemia vera, Prostate Cancer, Rare-cancers-and-associated-disorders, Renal Cell Carcinoma,

Second Preliminary Amendment
U.S. Application No.10/567,983
Ref. No. 007193-20 US

4

Retinoblastoma, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Salivary Gland Cancer, Sarcoma, Schwannoma, Sezary syndrome, Skin Cancer, Small Cell Lung Cancer (SCLC), Small Intestine Cancer, Soft Tissue Sarcoma, Spinal Cord Tumors, Squamous-Cell-Carcinoma-(skin), Stomach Cancer, Synovial sarcoma, Testicular Cancer, Thymus Cancer, Thyroid Cancer, Transitional-Cell-Cancer-(bladder), Transitional-Cell-Cancer-(renal-pelvis/-ureter), Trophoblastic Cancer, Urethral Cancer, Urinary System Cancer, Uroplakins, Uterine sarcoma, Uterus Cancer, Vaginal Cancer, Vulva Cancer, Waldenstrom's-Macroglobulinemia and Wilms' Tumor.

59. (New) The method according to Claim 58, wherein the cancer is selected from the group consisting of cancer of the breast, cancer of the kidney, cancer of the cervix, cancer of the lung, cancer of the rectum, cancer of the small intestine, cancer of the stomach, cancer of the ovary, cancer of the uterus, cancer of the vulva, cancer of the liver, cancer of the thyroid and cancer of the pancreas..

60. (New) A composition comprising (a) a compound selected from the group consisting of a modulator of expression of nucleic acid molecule having SEQ ID NO:5 and a modulator of the activity of a protein encoded by SEQ ID NO:5 and (b) a compound selected from the group consisting of a pharmaceutically acceptable carrier and a pharmaceutically acceptable diluent.

61. (New) A method of treating a mammal suffering from a cancer selected from the group consisting of cancer of the cervix, cancer of the lung, cancer of the ovary, cancer of the rectum and cancer of the uterus, said method comprising administering to said mammal a composition comprising a compound selected from the group consisting of a down-regulator of the expression of nucleic acid having SEQ ID NO:5 and a down-regulator of the activity of a protein encoded by SEQ ID NO:5.

62. (New) The method according to Claim 61, wherein the mammal is a human.

63. (New) A method of treating a mammal suffering from a cancer selected from the group consisting of cancer of the kidney, cancer of the breast, cancer of the pancreas, cancer of the liver, cancer of the small intestine, cancer of the stomach, cancer of the thyroid

and cancer of the vulva, said method comprising administering to said mammal a composition comprising a compound selected from the group consisting of an up-regulator of the expression of nucleic acid having SEQ ID NO:5 and an up-regulator of the activity of a protein encoded by SEQ ID NO:5.

64. (New) The method according to Claim 63, wherein the mammal is a human.

65. (New) A method for detecting cancer or predicting the likelihood of developing cancer in a mammal, said method comprising determining a factor selected from the group consisting of the level of expression of a nucleic acid having SEQ ID NO:5 and the level of activity of a protein encoded by a nucleic acid having SEQ ID NO:5 and comparing the results to a mammal not suffering from cancer.

66. (New) The method of Claim 65, wherein the cancer is selected from the group consisting of cancer of the breast, cancer of the kidney, cancer of the cervix, cancer of the lung, cancer of the rectum, cancer of the small intestine, cancer of the stomach, cancer of the vulva, cancer of the liver, cancer of the uterus, cancer of the ovary, cancer of the thyroid and cancer of the pancreas.